Quantcast

Latest Quark Stories

d6fda3a69cc555f4dcb43f43111ede771
2010-07-25 08:05:00

The Large Hadron Collider (LHC) is giving physicists hopeful candidates in the hunt for the heaviest elementary particle known to science. According to BBC News, so far their observations have been leading them in that direction. If the observations can be confirmed, it would be a first for Europe as the top quark particle has only been generated in one lab in the US. Dr Arnaud Lucotte, from the French National Centre of Scientific Research (CNRS), said the discovery could help physicists...

2010-05-04 08:00:00

FREMONT, Calif., May 4 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California. QPI-1002, the first systemically administered siRNA drug in humans, is designed to temporarily inhibit expression of the p53 stress-response gene. QPI-1002 is in...

2010-03-09 08:00:00

DENVER, March 9 /PRNewswire/ -- Virtela, the world's largest independent managed network services company, today announced that Quark Inc. has renewed its contract for global network services with Virtela. Since migrating to Virtela, Quark has reduced network costs by 30 percent and improved customer satisfaction and retention through better network and application performance. A leader in publishing for nearly 30 years, Quark provides dynamic publishing solutions for customers...

2010-03-01 08:00:00

FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007. This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION). The current trial represents the seventh clinical study of Quark...

2010-02-15 08:46:24

Data suggest symmetry may 'melt' along with protons and neutrons Scientists at the Relativistic Heavy Ion Collider (RHIC), a 2.4-mile-circumference particle accelerator at the U.S. Department of Energy's Brookhaven National Laboratory, report the first hints of profound symmetry transformations in the hot soup of quarks, antiquarks, and gluons produced in RHIC's most energetic collisions. In particular, the new results, reported in the journal Physical Review Letters, suggest that "bubbles"...

2010-01-05 07:30:00

FREMONT, Calif., Jan. 5 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing. This followed review of available safety data from two clinical trials for Quark's siRNA QPI-1002, at doses up to 10 mg/kg, the highest evaluated to date. QPI-1002 is designed to temporarily...

2009-11-29 12:19:03

Force of interaction between magnetic particles grows stronger with increasing distance An experiment has confirmed that spinons, particle-like magnetic excitations, can be confined in a magnetic insulator similar to the way elementary quarks are confined within individual protons and neutrons. The finding, in a well-described magnetic system, may offer new ways to explore Quantum Chromodynamics, the theory that describes the fundamental interactions of quarks. The observations of spinon...

2009-11-19 08:41:00

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the leader in siRNA therapeutics in clinicals, announced today that four of its siRNA R&D platform based programs have met clinical development milestones; patient enrollment was completed in three clinical studies and a new IND opened for ocular neuroprotection drug candidate QPI 1007: Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with...

2009-11-02 07:30:00

FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the 5th Annual Meeting of Oligonucleotide Therapeutics Society and...

2009-10-26 08:00:00

FREMONT, Calif. Oct. 26 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009. Granted to Quark from a Japanese National Phase application of International (PCT) Patent Application No. PCT/US98/17296, the patent corresponds to U.S. Patent No.s 6,455,674, 6,555,667 and...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related